FFR in the Time of ISCHEMIA

The results of this great multicenter “real-life” registry are similar to those of randomized clinical trials that studied fractional flow reserve (FFR).

Lesion deferral based on FFR is a very safe strategy, even for lesions located in the proximal anterior descending artery.

Randomized controlled studies FAME and DEFER convincingly showed the safety of lesion revascularization deferral based on FFR. However, we needed a prospective full-scale real-world study to confirm it.

This came with the J-CONFIRM registry conducted by Dr. Shoichi Kuramitsu and colleagues, recently published in Circulation Cardiovascular Interventions.


Read also: EuroPCR 2018 | FAME 2: FFR Shows 5-Year Benefit for Hard Endpoints.


Prestigious researchers such as Dr. William Fearon (main author of the FAME trial) said that this real-world registry with a long-term follow-up finally closes our information breach and confirms in a definitive way the safety of FFR.

The J-CONFIRM registry included 1263 patients in 28 Japanese sites between 2013 and 2015.

All of them were assessed through FFR and revascularized according to its result.

At 2 years, the rate of target vessel failure (the primary study endpoint) was 5.5% in deferred lesions. Almost all of these events were revascularizations justified by clinically driven target vessel revascularization (5.2%), i.e., plaque progression. Cardiac deaths or infarctions related to deferred lesions were very infrequent during follow-up (0.42%), enough to determine that deferred lesions are not a safety concern.


Read also: Clinical Events after Deferral of LAD Treatment Guided by FFR or iFR.


Notably, events were conversely associated with FFR value: the lower the value of this measurement, the higher the risk of events at 2 years. This was particularly true with proximal lesions. FFR has a cutoff value, but it is not a binary variable at all: it is a continuous variable.

Independent predictors of events in deferred lesions were baseline FFR value (observing it as a continuous variable), left main coronary artery lesions, moderate to severe calcification, need for hemodialysis, or right coronary artery lesions. With these factors, lesions can still be deferred, but we should conduct a closer follow-up.

As an example of that, we could say that a patient with baseline FFR 0.81 will present a higher rate of events than a patient with FFR 0.95; however, both can be deferred safely. We would simply need to plan a closer clinical follow-up for the first patient.

Original Title: Two-year outcomes after deferral of revascularization based on fractional flow reserve: the J-CONFIRM registry.

Reference: Kuramitsu S et al. Circ Cardiovasc Interv. 2020;12:e008355.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...